- Trxade
Group’s wholly owned subsidiary, Bonum Health, allows patients to access
medical advice from the comfort of their homes
- Telemedicine
is getting its moment in the clinical spotlight as COVID-19 contagion
fears are being addressed by limiting face-to-face human interaction
- Congress
has recently approved an $8.3 billion package which includes provisions
for Medicare providers to provide telehealth services to their patients
With large swathes of the population increasingly concerned
about leaving their homes and medical practitioners swamped amidst the ongoing
viral crisis, telemedicine is getting its moment in the clinical spotlight.
Bonum Health (http://ibn.fm/yvrNY),
the wholly owned subsidiary of Trxade Group Inc. (NASDAQ: MEDS), is a virtual telehealth
provider which helps patients easily and affordably access board-certified
physicians and receive medical prescriptions from the comfort of their homes.
Telemedicine has gained particular prominence in recent days
given the ongoing Coronavirus pandemic, which is primarily being tackled by
limiting human face-to-face interaction. Telemedicine boasts a number of
virtues – namely, the ability to offer customers a simplified and affordable
manner in which to access medical professionals via their laptop or
smartphones. However, it also enables patients who may be feeling unwell to
avoid hospitals and teeming patient waiting rooms where the risk of COVID-19
contagion is significantly heightened.
“What telehealth can do is help both the clinicians as well
as the consumer have access to service without actually getting exposed to the
virus,” Ann Mond Johnson, CEO of the American Telemedicine Association (ATA),
stated in a recent interview with ABC News. “It mitigates the risk. So in that
regard it’s incredibly valuable.”
On March 4, 2020, Congress approved an $8.3 billion
package (http://ibn.fm/G8r6e)
in emergency aid to combat the novel coronavirus, which included provisions for
Medicare providers to administer telehealth services so that elderly patients,
a particularly vulnerable demographic, could receive care at home. The aid
package was summarily followed by a coalition of private health insurers, who
after a meeting at the White House on March 10, 2020, stated that they would
pay for ‘virtual visits’ for patients who may have coronavirus so as to improve
access to care for their customers (http://ibn.fm/QK8pG).
In light of the news, Trxade Group is leveraging upon Bonum
Health’s unique healthcare platform to assist their members in gaining medical
assurance in a quick, easy and relatively inexpensive manner. “With the
seasonal flu outbreaks and the current coronavirus surge, patients are quick to
brush off common symptoms, include cough, fever and body aches, as signs of a
common cold”, Trxade Group’s news release states. “Telemedicine removes the
barrier of self-doubt and complacency in the current climate of world-wide
viral infections”. In an effort to further increase accessibility to their
services, Trxade Group announced the recent launch of a new membership service
from Bonum Health on March 10, 2020. The new service would allow subscribers to
obtain three premium medical teleconferencing visits and free prescription
delivery per month (http://ibn.fm/SFeSY).
Trxade Group is building a growing platform of integrated
drug procurement, delivery and healthcare services to facilitate price
transparency and increased profit margins for independent pharmacies within its
network as well as pharmaceutical product sellers.
For more information, visit the company’s website at www.TrxadeGroup.com
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
